Vetace Tablets 20mg (42 tabs)
This is a prescription medicine. A prescription is required from your veterinarian before we can supply this product. Please ensure that you have read the "How to Order" page before ordering this item.
All of our products are APVMA or TGA approved and identical to those used by your veterinarian. Please call or email us if you have any queries about any of the products on our site.
|Drug Name and Strength||Benazepril 20mg|
|Indication||Treatment of heart failure in dogs, and chronic renal insufficiency and hypertrophic cardiomyopathy in cats.Dogs. Treatment of left sided heart failure in dogs, most commonly resulting from mitral regurgitation (endocardiosis) and dilated cardiomyopathy. It inhibits the renin angiotensin aldosterone system, minimising the undesirable effects of vasoconstriction and sodium retention mediated by this system. The end result is an improvement in the clinical status of the dog, an extension of the life span of dogs with heart failure, and also improves clinical signs, notably reduction in coughing, and improvement to the quality of life. May be used in combination therapy with diuretics, for example frusemide, digoxin and antiarrhythmic drugs as necessary.Cats. Treatment of chronic renal insufficiency in cats. In such cats, it reduces protein loss in urine and lowers systemic and intraglomerular blood pressure. It increases quality of life, particularly in advanced cases, increases the survival time in cats with a urinary protein/creatinine ratio (UPC) equal to or exceeding 0.8 before treatment, and improves the appetite in cats with a UPC ratio exceeding 1.0. It has some beneficial effects on clinical signs and cardiac remodelling in cats with feline hypertrophic cardiomyopathy (HCM) and is well tolerated. Most cases of HCM in cats will require other additional medications of which the most commonly prescribed will be a calcium channel blocker, for example diltiazem.|
|Actions||Pharmacology Benazepril hydrochloride is a prodrug which is hydrolysed in vivo to benazeprilat, which inhibits the angiotensin converting enzyme (ACE), thus preventing the conversion of inactive angiotensin I into active angiotensin II. Benazepril hydrochloride reduces all effects mediated by angiotensin II, including vasoconstriction of both arteries and veins and retention of sodium and water by the kidney. It causes long lasting inhibition of plasma ACE in dogs and cats, with significant inhibition persisting for 24 hours after a single dose. ACE inhibitors may increase blood potassium levels, which may be beneficial when hypokalaemia associated with chronic renal insufficiency in cats occurs.Pharmacokinetics Benazepril hydrochloride is rapidly but incompletely absorbed from the gastrointestinal tract following oral administration. Absorbed benazepril is partially hydrolysed by hepatic enzymes to the active substance, benazeprilat; unchanged benazepril and hydrophilic metabolites account for the remainder. Peak plasma benazeprilat concentrations are attained within about two hours both in fasting and fed situations. Benazepril and benazeprilat are bound to plasma proteins, and in tissues are found mainly in the liver and kidney. The major part of benazeprilat is rapidly eliminated, although there is in addition a slow terminal elimination phase. Benazeprilat is excreted approximately equally via both biliary and urinary routes in dogs, and primarily via the biliary route in cats. Repeated administration of benazepril hydrochloride leads to slight accumulation of benazeprilat in plasma, and steady state is attained within four days. As it is excreted via the biliary route, there is little risk of bioaccumulation of benazeprilat in dogs or cats with impaired renal function. For this reason, no dose adjustment of the product is necessary in cases of renal insufficiency.|
|Precautions||Dogs. Clinical trials have shown benazepril hydrochloride to have good renal tolerance. Plasma urea and creatinine concentrations did not change and no evidence of renal toxicity of benazepril hydrochloride has been observed in dogs during clinical trials. The biliary excretion of benazeprilat means that there is little risk of bioaccumulation in dogs and cats with impaired renal function. However, as is routine in cases of renal insufficiency, it is recommended to monitor plasma urea and creatinine levels. Use during pregnancy and lactation. The safety of benazepril hydrochloride has not been tested in breeding dogs; therefore use is not recommended in pregnant or lactating bitches. No data are available in lactating bitches.Cats. Plasma creatinine concentrations may increase at the start of therapy. This effect is related to the therapeutic effect of the product in reducing glomerular capillary blood pressure, and therefore it is not necessarily a reason to stop therapy in the absence of other signs. Benazepril hydrochloride reduced erythrocyte counts in normal cats at high doses, but this effect was not observed at the recommended dose during clinical trials in cats with chronic renal insufficiency. Therefore, as is routine in cases of chronic renal insufficiency, it is recommended to monitor plasma creatinine and erythrocyte counts during therapy. Efficacy and safety has not been established in cats below 2.5 kg bodyweight. Use during pregnancy and lactation. The safety of benazepril hydrochloride has not been tested in breeding cats, or pregnant or lactating queens, therefore use only if justified clinically, considering the risk/benefit ratio. Benazepril hydrochloride reduced ovary and oviduct weights when administered daily at 10 mg/kg for 52 weeks. ACE inhibitors have been found to be teratogenic in the second and third trimesters in other species.First Aid If poisoning occurs contact a doctor or Poisons Information Centre. Phone Australia 131 126.Disposal Dispose of empty container by wrapping with paper and placing in garbage.|
|Dosage and Administration||Give orally, once daily, with or without food.Dogs. The minimum recommended oral dose for heart failure in dogs is 0.25 mg/kg with the dose doubled, still administered daily, if judged clinically necessary and advised by the veterinary surgeon. Dogs 2.5 to 5 kg. Half a 2.5 mg tablet. 5 to 10 kg. One 2.5 mg tablet, or half a 5 mg tablet. 11 to 20 kg. One 5 mg tablet. 21 to 40 kg. Half a 20 mg tablet. 41 to 80 kg. One 20 mg tablet.Cats. The minimum recommended oral daily dose for chronic renal insufficiency and hypertrophic cardiomyopathy in cats is 0.5 mg/kg bodyweight. Cats 2.5 to 5 kg. One 2.5 mg tablet, or half a 5 mg tablet. 5 to 10 kg. Two 2.5 mg tablets, or one 5 mg tablet.|
|Storage||Store below 30°C (room temperature). Protect from heat and moisture. Unused half tablets should be returned to the open blister space and inserted back into the carton.|
|MSDS (external link)||Vetace Tablets 20mg MSDS|
|Label (external link)||Vetace Tablets 20mg Label|
|Manufacturer||Jurox Pty Limited|